glp 1 journal The expanding landscape of GLP-1 medicines GLP-1 Weight Loss Journal &

The GLP-1 market is expected to hit $200 billion by 2031, according to a new study.

Heart failure (HF) affects 6 million people in the US, and type 2 diabetes (T2D) is a significant risk factor for HF

Is microdosing semaglutide or tirzepatide safe

[1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03309241&atom=%2Fbiorxiv%2Fearly%2F2020%2F09%2F30%2F2020.09.29.319483.atom

These medications work by mimicking the action of GLP-1, thereby helping to regulate blood sugar levels and reduce appetite

Clinician-focused drug-drug interaction reference for GLP-1 receptor agonists including semaglutide, liraglutide, dulaglutide, tirzepatide, and exenatide